Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71209-020

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71209-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil-spl-cont-label-10mg-1000tab (Donepezil Spl Cont Label 10mg 1000tab)

Donepezil Hydrochloride Tablets USP 10 mg film-coated tablets label showing dosage form and strength. The label includes storage instructions, dispensing information, and manufacturer details for Cadila Pharmaceuticals Limited, India. It features a purple design with a barcode and indicates the package contains 1000 tablets for oral administration.*

FDA Label Image

Donepezil-spl-cont-label-10mg-30tab (Donepezil Spl Cont Label 10mg 30tab)

Label for Donepezil Hydrochloride Tablets USP 10 mg film-coated tablets, oral use. The label shows the product name, strength, form, and quantity (30 tablets), with storage instructions and manufacturer information (Cadila Pharmaceuticals Ltd., Ahmedabad, India). It also includes a barcode and a dosage use note directing to accompanying prescribing information.*

FDA Label Image

Donepezil-spl-cont-label-10mg-90tab (Donepezil Spl Cont Label 10mg 90tab)

Donepezil Hydrochloride Tablets USP 10 mg film-coated tablets label from Cadila Pharmaceuticals Limited. The label indicates 90 tablets per container, includes storage instructions (controlled room temperature 15-30°C), dosage use note referencing the prescribing information, and dispensing instructions. The label also shows the NDC 71209-020-04 and a barcode.*

FDA Label Image

Donepezil-spl-cont-label-5mg-1000tab (Donepezil Spl Cont Label 5mg 1000tab)

Donepezil Hydrochloride Tablets USP 5 mg film-coated tablets packaging label from Cadila Pharmaceuticals Limited. The label indicates that each tablet contains 5 mg of donepezil hydrochloride and includes storage instructions for controlled room temperature. The package contains 1000 tablets and is labeled for prescription use only.*

FDA Label Image

Donepezil-spl-cont-label-5mg-30tab (Donepezil Spl Cont Label 5mg 30tab)

Label for Donepezil Hydrochloride Tablets USP 5 mg film-coated tablets in a package of 30, manufactured by Cadila Pharmaceuticals Limited. The label includes storage instructions, a barcode, and notes that the tablets are prescription only. The manufacturer address is in Ahmedabad, Gujarat, India.*

FDA Label Image

Donepezil-spl-cont-label-5mg-90tab (Donepezil Spl Cont Label 5mg 90tab)

Label for Donepezil Hydrochloride Tablets USP 5 mg oral film-coated tablets, manufactured by Cadila Pharmaceuticals Limited. The label indicates each tablet contains donepezil hydrochloride USP 5 mg, with packaging for 90 tablets. Storage instructions specify controlled room temperature (59° to 86°F/15° to 30°C) and dispensing in tight containers. The label includes dosage and use reference to accompanying prescribing information, barcode, and a note about serialized datamatrix code and batch coding space.*

FDA Label Image

Fig1 (Donepezil Spl Fig 01)

A line graph showing the ADAS-cog change from baseline over 30 weeks in patients treated with Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day compared with placebo. The X-axis represents weeks of drug treatment, and the Y-axis shows the mean change from baseline, with clinical improvement upward and clinical decline downward. Error bars indicate standard error.*

FDA Label Image

Fig2 (Donepezil Spl Fig 02)

A cumulative percentage plot showing patient response over changes from baseline in ADAS-cog scores. It compares Donepezil Hydrochloride Tablets at 5 mg/day and 10 mg/day doses against placebo, labeling key improvement points at 7, 4, and no change. The inset table reports percentages of patients in each treatment group achieving these levels of cognitive change.*

FDA Label Image

Fig3 (Donepezil Spl Fig 03)

Bar graph showing patient percentage distribution by CIBIC-plus rating categories for Donepezil Hydrochloride tablets at 10 mg/day, 5 mg/day, and placebo groups. Categories range from markedly improved to markedly worse, highlighting differences in patient outcomes among the three groups.*

FDA Label Image

Fig4 (Donepezil Spl Fig 04)

A line graph showing the change from baseline ADAS-cog scores over 15 weeks of treatment. It compares Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day dosages to placebo, illustrating clinical improvement trends in cognitive function during drug treatment and clinical decline during the placebo phase.*

FDA Label Image

Fig5 (Donepezil Spl Fig 05)

A cumulative percentage graph showing the change from baseline in ADAS-cog scores for Donepezil Hydrochloride tablets at 5 mg/day, 10 mg/day, and placebo treatment groups. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. Marks indicate points at -7 and -4 improvements and no change at 0. A table presents percentage improvements and no change rates for each group.*

FDA Label Image

Fig6 (Donepezil Spl Fig 06)

A bar chart depicting the CIBIC-plus rating of patients treated with Donepezil Hydrochloride tablets at 5 mg/day and 10 mg/day doses, compared to placebo. The vertical axis shows the percentage of patients, and the horizontal axis categorizes patient responses from markedly improved to markedly worse.*

FDA Label Image

Fig7 (Donepezil Spl Fig 07)

Line graph showing the change from baseline in SIB (Severe Impairment Battery) scores over 6 months of drug treatment. It compares Donepezil Hydrochloride Tablets 10 mg/day versus placebo, illustrating clinical improvement or decline relative to baseline. Data points include mean values with standard error bars at months 0, 3, and 6.*

FDA Label Image

Fig8 (Donepezil Spl Fig 08)

A cumulative percentage of patients line graph comparing Donepezil Hydrochloride 10 mg/day tablets to placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, and the y-axis represents the cumulative percentage of patients, illustrating patient response over the range of SIB score changes.*

FDA Label Image

Fig9 (Donepezil Spl Fig 09)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment. The graph compares Donepezil Hydrochloride Tablets 10 mg/day and placebo, showing their respective trends in clinical improvement or decline.*

FDA Label Image

Fig10 (Donepezil Spl Fig 10)

A cumulative percentage line graph comparing Donepezil Hydrochloride 10 mg/day tablets versus placebo in terms of ADCS-ADL change from baseline. The x-axis shows ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients. Two lines indicate patient outcomes for donepezil and placebo groups.*

FDA Label Image

Fig11 (Donepezil Spl Fig 11)

A line graph depicting clinical response to Donepezil Hydrochloride Tablets at daily doses of 10 mg and 23 mg over 24 weeks of treatment. The vertical axis shows change from baseline in SIB score, measuring clinical improvement or decline, with data points and error bars plotted for both doses across the weeks.*

FDA Label Image

Fig12 (Donepezil Spl Fig 12)

A cumulative percentage of patients graph comparing donepezil hydrochloride tablets at 10 mg/day and 23 mg/day dosages. The x-axis shows SIB change from baseline, and the y-axis shows cumulative patient percentages, illustrating the distribution of patient responses for both dosage strengths.*

FDA Label Image

Fig13 (Donepezil Spl Fig 13)

A bar chart comparing the percentages of patients showing different CIBIC-plus Ratings for Donepezil Hydrochloride Tablets at dosages of 23 mg/day and 10 mg/day. Categories range from Markedly Improved to Markedly Worse with proportions shown for each rating.*

FDA Label Image

Str (Donepezil Spl Struc)

Chemical structure of donepezil hydrochloride, depicting its molecular framework with characteristic aromatic rings and functional groups as shown in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.